Novartis said it’s working to get the most out of its $12 billion acquisition of Avidity Biosciences by finding ways to apply its underlying science to diseases beyond muscular dystrophy.
The drugmaker’s 2025
After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.
The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with chronic liver disease.
A $140m fund launched by philanthropic group Coefficient Giving will try to find the first vaccine for Strep A, which kills 639,000 people a year.
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a
Novartis said it’s working to get the most out of its $12 billion acquisition of Avidity Biosciences by finding ways to apply its underlying science to diseases beyond muscular dystrophy.
The drugmaker’s 2025